PULMATRIX INC (PULM)
US74584P3010 - Common Stock
PULM Stock Earnings: Pulmatrix Beats EPS, Beats Revenue for Q4 2023
PULM stock results show that Pulmatrix beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
PULM Stock Earnings: Pulmatrix Beats EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pulmatrix (NASDAQ:PULM) just reported results for the fourth quarter of 2023.Pu...
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives
/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
/PRNewswire/ -- Pulmatrix, Inc. (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine
/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious...
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...
Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...
Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...
Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...
Pulmatrix Supports World Asthma Day 2023
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...
Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...
Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease...
Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease...
PULM stock drops on early data for inhaled migraine therapy (NASDAQ:PULM)
Pulmatrix, Inc. (PULM) dropped ~18% in the morning hours Wednesday after announcing topline results from a Phase 1 trial for its migraine therapy PUR3100. Read the full story here.
Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease...
Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease...
Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease...
Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...
Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...
Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...
Pulmatrix Regains Compliance With Nasdaq Listing Requirements
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...
Which U.S. Companies Are Cutting Ties With Russia? See Latest List.
U.S. companies are cutting ties with Russia due to the war with Ukraine and we're going over which ones traders need to know about.